People walk past electric truck manufacturer Rivian’s newly opened store in Manhattan’s Meatpacking District on June 23, 2023 in New York City.

Spencer Platt | Getty Images

Take a look at the companies making the headlines in midday trading.

Electric cars — Manufacturers of electric vehicles, such as Rivian Automotive rose after Tesla’s better-than-expected production and delivery numbers in the second quarter. Rivian jumped 14%, Fisker increased by 4% and Lucid Group advanced 5%.

XPeng — US-listed shares of XPeng rose more than 4%. The Chinese electric vehicle manufacturer has returned to growth in car deliveries. In the second quarter, it delivered 23,205 vehicles, representing a quarter-on-quarter increase of 27%.

Tesla — Shares of the Elon Musk-led electric vehicle company jumped 6% afterward. delivery and production numbers beat analysts’ expectations. The second quarter of 2023 was the fifth in a row that Tesla reported a higher level of vehicles produced compared to deliveries.

Chinese Internet Stocks — Tech names rose in China on Monday. The KraneShares CSI China Internet ETF added more than 3%, lifted the stock Alibabahigher by 1%, a Pinduoduowith a lead of 4%. Actions from gained 4%.

Solar shares — Solar shares SolarEdge technology and Enphase Energy rose more than 2% and 1% on Monday.

Semiconductors — Semiconductor names rose on Monday. Actions from Marvell technology and Micron technology were each higher by more than 1%.

Apple — Apple fell 0.5% after the Financial Times, citing people with direct knowledge of the matter, announced that the iPhone maker was forced to cut production forecasts for the Vision Pro headset. Apple shares closed at the top on Friday, a market value of $3 trillion.

AstraZeneca — Shares fell about 8% after the Cambridge, England-based drugmaker he announced disappointing preliminary results of the third phase of the study of the treatment of lung cancer. AstraZeneca said it slowed cancer progression, but data on overall survival was “not mature” and the results were not statistically significant. The study will continue to evaluate overall survival with greater maturity, the company said.

— CNBC’s Michelle Fox and Yun Li contributed reporting

Source Link